NewsResearch
FDA Approval: Trastuzumab deruxtecan (Enhertu) for Breast cancer
FDA approved Trastuzumab deruxtecan (Enhertu), an antibody-drug conjugate, for certain people with breast cancer. What was approved, the evidence, and what it does and doesn't mean.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
In brief
FDA approved Trastuzumab deruxtecan (Enhertu) — antibody-drug conjugate — for certain people with breast cancer. This page explains what that means in plain language and where the limits are.
Approval at a glance
| Field | Detail |
|---|---|
| Drug | Trastuzumab deruxtecan (Enhertu) |
| Regulator | FDA |
| Date | 2019 |
| Cancer type | Breast cancer |
| Treatment class | antibody-drug conjugate |
| Eligible population | Certain people with breast cancer |
| Approval type | first approval |
What was approved
Trastuzumab deruxtecan (Enhertu) (antibody-drug conjugate) received a first approval from the FDA for use in certain people with breast cancer, reported for 2019. Eligibility is defined by the official label; whether it fits a specific person is a clinical decision.
The evidence behind it
The approval was based on the clinical evidence summarized in the FDA's announcement and the product label.
What this does and doesn't change
Approvals like this can expand options for certain people with breast cancer, but they do not change care for everyone, and access, cost, and side effects still matter.
What this story cannot tell you
- An approval defines who is eligible in general terms; whether it fits a specific person is an individual clinical decision.
- Approval is not a promise of cure or of benefit for every patient — it means the evidence met the regulator's bar for this use.
- Labels and evidence can change over time as more data arrive.
Questions worth asking
- Am I in the group this treatment was approved for?
- How does it compare with my current options?
- What are the costs, logistics, and side effects?
Sources
This article was written from the sources below, which were checked on the source-check date shown above.
- PubMed FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for HER2-Positive Breast Cancer (official)
- Enhertu FDA approval history (first approval Dec 2019) (secondary)
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.